Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down prior to trading on Tuesday . The stock had previously closed at $28.38, but opened at $27.31. Ascentage Pharma Group International shares last traded at $27.31, with a volume of 633 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on AAPG shares. Lucid Cap Mkts raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. BTIG Research assumed coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price objective on the stock. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research note on Monday, November 24th. Rodman & Renshaw initiated coverage on Ascentage Pharma Group International in a report on Tuesday. They issued a “buy” rating and a $48.00 price target on the stock. Finally, Piper Sandler assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus target price of $48.40.

Ascentage Pharma Group International Price Performance

The company has a debt-to-equity ratio of 1.31, a current ratio of 1.54 and a quick ratio of 1.53. The stock has a 50-day simple moving average of $30.08 and a 200-day simple moving average of $36.09.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several hedge funds have recently made changes to their positions in the stock. Chevy Chase Trust Holdings LLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $227,000. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International during the second quarter valued at about $391,000. Tema Etfs LLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $610,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ascentage Pharma Group International in the third quarter valued at approximately $96,000. Finally, ABC Arbitrage SA purchased a new position in Ascentage Pharma Group International during the third quarter valued at approximately $204,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.